Price
No data yet.
Social Signal Score
Analyst Ratings
3 analystsRevenue
$0.00Analyst Estimates
Consensus estimates, not results. Via Financial Modeling Prep.
Company Profile
- CEO
- Robert Bancroft
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 8
- Beta
- 0.65
- Country
- US
- Piotroski score
- 2 / 9 (Weak)
- Altman Z-score
- -129.31
Financials
Net Income
$-1.16MEBITDA
$-5.91MFree Cash Flow
$-3.70MEPS (diluted)
$-0.02Shares Outstanding (diluted)
50.53M+2520.3%Operating Expenses
$5.91MCash & Debt
$3.43MQuote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $0.00 | $-39.22M | $-3.95 |
| 2024 | $0.00 | $42.01M | $77.74 |
| 2023 | $0.00 | $-384.63M | $-744.83 |
| 2022 | $0.00 | $-52.56M | $-27.25 |
| 2021 | $0.00 | $-55.64M | $18.86 |
| 2020 | $2.52M | $-32.91M | $-0.01 |
| 2019 | $3.36M | $172.92M | $1481.04 |
Valuation
AEONhas no positive reported earnings per share, so an earnings-multiple projection can't be built for it. Companies are valued on other measures at this stage — revenue growth, cash burn, or book value — none of which this calculator models.
Signal Score (90d)
87-13.33%Social Signal Score
Mentions (5)
- Newsglobenewswire.com·6d ago·Negative
AEON Biopharma FDA Type 2b Meeting Feedback Clarifies Biosimilar Development Plan for ABP-450 FDA indicated previously completed ABP-450 head-to-head studies versus BOTOX® may be submitted as supportive evidence; AEON expects to advance the required scientific bridging work AEON plans to submit an IND for CMAP pharmacodynamic study in the fourth quarter of 2026 AEON plans to leverage its analytical, pharmacodynamic, and existing comparative human evidence to support a potential streamlined devel…
View source ↗ - Newsglobenewswire.com·36d ago·Positive
AEON Biopharma to Participate in Lake Street Capital Markets' 10th Annual Best Ideas Growth (BIG10) Conference ALISO VIEJO, Calif., Aug. 31, 2026 (GLOBE NEWSWIRE) -- AEON Biopharma, Inc. (“AEON” or the “Company”) (NYSE American: AEON), a biopharmaceutical company advancing ABP-450 as a biosimilar to BOTOX® (onabotulinumtoxinA) for therapeutic use to achieve full-label U.S. market entry, announced today that AEON management will host in-person 1x1 investor meetings at Lake Street Capital Markets'…
View source ↗ - Newsglobenewswire.com·43d ago·Neutral
AEON Biopharma Designates Former FDA Neuroscience Leader Paul Lee, M.D., Ph.D. as Acting Chief Regulatory Officer - Former Deputy Director of the FDA's Office of Neuroscience - Dr. Lee has previously advised AEON through Clintrex Research LLC (Clintrex), an affiliate of BlueRidge Life Sciences, on the regulatory strategy for ABP-450 ALISO VIEJO, Calif., Aug. 24, 2026 (GLOBE NEWSWIRE) -- AEON Biopharma, Inc. (“AEON” or the “Company”) (NYSE American: AEON), a biopharmaceutical company advancing A…
View source ↗ - Newsglobenewswire.com·48d ago·Neutral
AEON Reports Expanded Structural Data Supporting Molecular Similarity of ABP-450 to BOTOX® - Complementary peptide-mapping methods increased coverage of the active botulinum neurotoxin primary sequence from approximately 93% to 98%, with 100% amino acid identity across all regions analyzed
View source ↗ - Newsglobenewswire.com·54d ago·Neutral
AEON Biopharma Reports Second Quarter 2026 Financial Results and Provides Corporate Update - Executed a $15.3 million financing with milestone warrants providing potential for an additional $34.0 million in gross proceeds, supporting continued advancement of ABP-450's development program
View source ↗
Earnings
Fri, Nov 13(in 5 weeks)
Consensus estimate $-0.07 per share
Typical surprise +91.1% (median, so one quarter with a near-zero estimate can't distort it)
- Wed, Aug 12$-0.02 vs $-0.23beat
- Thu, May 14$-0.44 vs $-0.44beat
- Mon, Mar 30$-5.24 vs $-0.17miss
- Fri, Nov 14$-0.39 vs $-0.43beat
- Mon, Aug 11$-0.60 vs $-11.51beat
- Wed, May 14$2.28 vs $-13.67beat
Estimates and results for AEON via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Insider trading
Open-market buys and sells by AEON officers and directors.
- Bought
- $328k
- Sold
- $73.8m
4 trades
1 trade
- Lynch Timothy Pbought
- Fischer Jostbought
- Fischer Jostbought
- Fischer Jostbought
- Strathspey Crown Holdings Group, Llcsold
95 further Form 4 entries are share awards, option exercises or shares withheld for tax. Those are compensation, not trades, so they are excluded above. Buying is the stronger signal: an insider spends their own money for one reason. Selling has many innocent explanations — tax, diversifying, a house — so it says far less than it appears to. Via SEC filings.
Congress trades
No disclosed congressional trades in AEON.
Self-reported filings, amounts as brackets. Via Senate/House disclosures.